Cargando…
Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung
There is a large, unmet medical need to treat chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis and other respiratory diseases. New modalities are being developed, including gene therapy which treats the disease at the DNA/RNA level. Despite recent innovations in non-viral...
Autores principales: | de Braganca, Leonor, Ferguson, G. John, Luis Santos, Jose, Derrick, Jeremy P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788408/ https://www.ncbi.nlm.nih.gov/pubmed/33956565 http://dx.doi.org/10.1080/1547691X.2021.1902432 |
Ejemplares similares
-
Comparing Natural Product (NP) and non-NP datasets at an atomic scale
por: Heintz, Tobias, et al.
Publicado: (2008) -
Non-viral siRNA delivery to the lung()
por: Thomas, Mini, et al.
Publicado: (2007) -
Adverse events for biologics in patients with CRSwNP: A meta‐analysis
por: Shen, Yang, et al.
Publicado: (2022) -
The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
por: Holder, Jessica E., et al.
Publicado: (2023) -
Comparison of methods to detect the in vitro activity of silver nanoparticles (AgNP) against multidrug resistant bacteria
por: Cavassin, Emerson Danguy, et al.
Publicado: (2015)